Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Many facets of bortezomib resistance/susceptibility.

Literature DB >> 18779399

Many facets of bortezomib resistance/susceptibility.

Shaji Kumar¹, S Vincent Rajkumar.
1. Mayo Clinic, USA.

Abstract

Entities: Chemical

Year: 2008 PMID： 18779399 DOI： 10.1182/blood-2008-07-167767

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

29 in total

1. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors:
Journal: Am J Hematol Date: 2018-08-16 Impact factor: 10.047

Review 2. Next-generation proteasome inhibitors for cancer therapy.

Authors: Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal: Transl Res Date: 2018-03-26 Impact factor: 7.012

3. Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.

Authors: Ryan T VanderLinden; Casey W Hemmis; Tingting Yao; Howard Robinson; Christopher P Hill
Journal: J Biol Chem Date: 2017-04-25 Impact factor: 5.157

4. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Authors: S Vincent Rajkumar
Journal: Am J Hematol Date: 2012-01 Impact factor: 10.047

5. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Authors: A K Mitra; U K Mukherjee; T Harding; J S Jang; H Stessman; Y Li; A Abyzov; J Jen; S Kumar; V Rajkumar; B Van Ness
Journal: Leukemia Date: 2015-12-29 Impact factor: 11.528

6. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.

Authors: Maria Vaiou; Evanthia Pangou; Panagiotis Liakos; Nikos Sakellaridis; George Vassilopoulos; Konstantinos Dimas; Christos Papandreou
Journal: J Cancer Res Clin Oncol Date: 2016-08-16 Impact factor: 4.553

Many facets of bortezomib resistance/susceptibility.

1. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Review 2. Next-generation proteasome inhibitors for cancer therapy.

3. Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.

4. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

5. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

6. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.

7. Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex.

Review 8. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

9. Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients.

10. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.